Grifols Study Demonstrates Higher Dose of PROLASTIN-C Increases Levels of Alpha1-PI to Within Normal Range in Patients With AAT Deficiency
5/22/2013 10:17:11 AM
More...
|
Grifols Signs Deal to License Aradigm Corporation (ARDM)'s Pulmaquin for Up to $90.7 Million
5/21/2013 7:01:13 AM
More...
|
Grifols Acquires 60 Pct Stake in Progenika for $48 Million
3/8/2013 7:21:03 AM
More...
|
Grifols Announces First Patient Enrolled and Dosed in Phase II Trial of Alpha-1 HC Aerosol to Treat Cystic Fibrosis
10/8/2012 10:50:36 AM
More...
|
Grifols Announces Robust Inventory of Hyperrab® S/D Rabies Immune Globulin for Treatment of Rabies Exposure
10/1/2012 12:10:33 PM
More...
|
Grifols Initiates Safety Study of Inhaled Alpha1-Proteinase Inhibitor (Human) Following Orphan Drug Designation for Cystic Fibrosis
7/17/2012 10:08:50 AM
More...
|
Grifols Has Acquired 51% of the Capital of Araclon Biotech to Ensure the Viability of the Purchased Company Projects
3/16/2012 7:54:50 AM
More...
|
Grifols Announces New North American Commercial Operations Organization
8/2/2011 1:09:34 PM
More...
|
Health Robotics and Grifols Expand Marketing Cooperation Into the United States of America, Replacing McKesson
7/25/2011 11:37:42 AM
More...
|
Grifols' CEO Sees Few Cuts at Talecris Biotherapeutics (TLCR); Expects Layoffs to be Less Than 5%
6/8/2011 6:46:48 AM
More...
|
|